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Abstract Over recent years, significant progress has been
made in characterisation of the underlying pathogenic mech-
anisms in psoriasis, a common cutaneous disease that is asso-
ciated with major systemic co-morbidity and reduced life ex-
pectancy. Basic science discoveries have informed the design
of novel therapeutic approaches, many of which are now un-
der evaluation in late-stage clinical trials. Here we describe the
complex interplay between immune cell types and cytokine
networks that acts within self-perpetuating feedback loops to
drive cutaneous inflammation in psoriasis. Genetic studies
have been pivotal in the construction of the disease model
and more recently have uncovered a distinct aetiology for rare,
pustular variants of psoriasis. The translation of mechanistic
insights into potential advancements in clinical care will also
be described, including several treatments that target the
interleukin-23 (IL-23)/T17 immune axis.
Introduction
The therapeutic armamentarium for psoriasis has expanded
over the past two decades with the development of several
highly selective therapies that are both efficacious and have
a favourable safety profile. Novel insights into psoriasis
immunopathogenesis have informed the design of these treat-
ments, and in turn, mechanistic studies within clinical trials
are helping to further characterise the role of different cellular
players and cytokine axes in the pathogenic disease model.
Psoriasis is a phenotypically heterogeneous, immune-
mediated skin condition that often follows a relapsing and
remitting course. It is a common, complex trait that affects
approximately 2 % of the general population and is associated
with multiple co-morbidities including arthritis, cardiovascu-
lar disease, obesity, hypertension, diabetes mellitus, reduced
quality of life and depression [1–4]. Almost 90 % of individ-
uals have psoriasis vulgaris and the majority of research to
date (as described in this review) has investigated this form
of the disease. It is characterised by well-demarcated, scaling,
erythematous plaques that frequently manifest at sites of trau-
ma (extensor aspects of elbows, knees), however can appear
anywhere on the body. Approximately one third of patients
have moderate to severe disease, which affects more than
10 % of body surface area, and usually necessitates systemic
medications. Other clinical variants include pustular psoriasis,
guttate psoriasis and erythroderma. Emerging evidence indi-
cates that the distinct phenotypes have different immunoge-
netic profiles, which will likely influence treatment choices
[5]. Discoveries from genetics and immunology research have
converged to shape the current pathogenic model for psoriasis.
In particular, hypothesis-free large-scale case–control genetic
analyses such as genome-wide association studies (GWAS)
have highlighted key roles for the regulation of specific innate
and adaptive immune pathways, such as antiviral responses
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and the IL-23/T17 axis, respectively, which have been sub-
stantiated by immunological data [6].
Pathogenic model for psoriasis
The pathogenesis of psoriasis involves dynamic interactions
between multiple cell types and numerous cytokines in re-
sponse to triggers, culminating in the disruption of skin im-
mune homeostasis in genetically predisposed individuals. The
histological features of a psoriatic plaque provide an insight
into the immunological complexities of the disease. There is
thickening of the epidermis (acanthosis) due to an increase in
keratinocyte turnover [7]. The retention of keratinocyte nuclei
in the stratum corneum (parakeratosis) due to abnormal dif-
ferentiation further highlights the importance of these skin
cells in the development of psoriasis. Psoriatic lesions are also
densely infiltrated by T cells and dendritic cells (DC). These
immune effectors produce pro-inflammatory cytokines such
as tumour necrosis factor α (TNFα), interferon γ (IFNγ),
interleukin-17 (IL-17), IL-22, IL-23 and IL-1β. Neutrophils
collect in the epidermis and form collections called Munro’s
microabscesses. Plaques are highly vascular and new vessel
formation is mediated by angiogenic factors such as vascular
endothelial growth factor (VEGF).
The initiation phase of a psoriatic lesion involves a close
interplay between external factors and genetic alterations that
predispose to the phenotype [3]. Triggers include physical
injury (which causes Koebner phenomenon), infections (par-
ticularly streptococcal) and medications (e.g. β-blockers, lith-
ium). Although the exact mechanisms for the induction of
psoriasis are not yet fully elucidated for many of these envi-
ronmental factors, some insults such as physical trauma cause
the release of the antimicrobial peptide LL37 (cathelicidin) by
keratinocytes, which then mediates the breakdown of toler-
ance to self-nucleic acids (Fig. 1). LL37 binds with
pathogen-derived DNA or self-DNA that has been released
by stressed or dying cells and forms complexes that activate
Toll-like receptor 9 (TLR9) on plasmacytoid DCs [8, 9]. This
promotes type I IFN release, which, along with TNFα, IL-6
and IL-1β, activates local myeloid DCs, thus promoting T
cell-mediated inflammation. There is also evidence that
LL37 may directly activate auto-reactive circulating T cells,
and this phenomenon was more prevalent in psoriasis patients
with greater disease activity [10].
Myeloid DCs migrate into draining lymph nodes and re-
lease cytokines including TNFα, IL-23 and IL-12 that activate
allogeneic T cells (Fig. 2). Once activated, T cells enter the
circulation and move towards inflamed skin through interac-
tions with adhesion molecules (including P-selectin and E-
selectin) on the endothelial cells of blood vessels. The effector
molecules secreted by T cells then activate keratinocytes,
resulting in the release of cytokines and chemokines that
continue to recruit and activate inflammatory cells. For exam-
ple, IFNγ, IL-17 and IL-22 are secreted by T helper type 1
(Th1), Th17 and Th22 cells, respectively, which contribute to
the amplification of cutaneous inflammation.
LL37 may also bind to self-RNA and directly activate my-
eloid DCs via TLR7 and TLR8 [11]. This results in the up-
regulation of TNFα and IL-6. In support of this disease initi-
ation model, the TLR7/8 agonist imiquimod has been shown
to induce psoriasiform skin inflammation in mouse models
[12]. These changes were blocked in mice deficient for the
IL-23 or IL-17 receptor, which indicates a role for crosstalk
between keratinocytes and the IL-23/T17 pathway in the path-
ogenesis of psoriasis.
The following sections summarise the roles of specific cells
and cytokines in initiating and maintaining the dysregulated
immune response that leads to psoriasis. An update on the
therapeutic agents currently available and in clinical trial stage
is also included.
The role of immune cell types in psoriasis
Dendritic cells
DCs are professional antigen presenting cells that activate T
cells and are an important source of pro-inflammatory cyto-
kines and chemokines in psoriasis. Genetic studies indicate a
fundamental role for antigen presentation in the disease pro-
cess since the PSORS1 interval on chromosome 6p21.3 con-
fers the greatest risk and is the most replicated locus for pso-
riasis [13–15]. The likely causal allele within PSORS1 is
HLA-Cw6, which encodes a class I major histocompatibility
complex (MHC) molecule that is expressed by antigen pre-
senting cells and mediates T cell activation [16, 17]. It is esti-
mated to account for approximately 50 % of disease heritabil-
ity and the odds ratios observed in GWAS have ranged be-
tween 2.6 and 4.7 [18–21]. Genetic variants within ERAP1
interact with HLA-Cw6 (genetic epistasis), such that ERAP1
risk alleles are only associated with psoriasis susceptibility in
individuals harbouringHLA-Cw6 [19]. The protein product of
ERAP1 trims peptides to enable effective loading onto MHC
class I molecules, thus reinforcing the role for antigen presen-
tation and subsequent abnormal Tcell activation in the disease
model.
The main lineages of DCs that have been characterised in
psoriasis are plasmacytoid DCs and myeloid DCs. They lo-
calise to the dermis and express distinct cell surface markers.
The αx integrin CD11c is a marker of myeloid DCs, which are
considered to be important in the early stages of disease. The
blood DC antigens (BDCA) identify different subsets of my-
eloid DCs, such as BDCA-1+ ‘resident’ DCs and BDCA-1−
‘inflammatory’ DCs. The latter have been found in greater
numbers in the dermis of lesional psoriatic skin compared
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with non-lesional or normal skin [22–24] and decrease in
number following effective psoriasis treatment [24, 25].
Plasmacytoid DCs are a rich source of type I IFN, an early
signature cytokine in psoriasis, and have been found at
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Fig. 1 Schema for the initiation of a psoriatic skin lesion. Triggers such
as trauma and infections lead to the release of self-DNA and self-RNA,
which form complexes with LL37 and activate plasmacytoid dendritic
cells (pDCs) and myeloid dendritic cells (mDCs), respectively. pDCs
secrete type I interferons (IFN) and other cytokines including TNFα,
IL-6 and IL-1β, which promote the activation of mDCs. These antigen
presenting cells release pro-inflammatory cytokines that drive T cell-
mediated inflammation and keratinocyte activation and proliferation.
This promotes the recruitment and activation of further inflammatory
cells such as neutrophils and macrophages, contributing to the
formation of an inflamed cutaneous plaque. AMPs antimicrobial peptides
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Fig. 2 Schema of the contribution of Tcell subsets to the pathogenesis of
psoriasis. Activated myeloid dendritic cells (mDC) release cytokines that
promote the differentiation of populations of resident T cells into Th22,
T17 and Th1 cells. Cytokines secreted by these effector T cells stimulate
keratinocytes, which promote the recruitment of other inflammatory cells
such as neutrophils by release of chemokines. Activation of autocrine and
paracrine feedback loops culminates in the development and maintenance
of cutaneous inflammation. AMPs antimicrobial peptides, VEGF vascular
endothelial growth factor
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increased levels in lesional skin compared with normal skin
[26–28]. Plasmacytoid DCs help to initiate disease and are
activated by LL37/DNA complexes, as described above.
The importance of this cell type in the disease model has been
supported by xenotransplantation models of psoriasis, in
which non-lesional skin from patients with psoriasis are
grafted onto athymic nude mice (deficient in T cells) or those
with severe combined immunodeficiency (without T and B
cells) [29]. In these experimental systems, inhibition of type
I IFN release or signalling by plasmacytoid DC blocked path-
ogenic T cell activation, which prevented the development of
psoriasis [15, 16].
Langerhans cells are skin-resident immune cells that asso-
ciate closely with keratinocytes in the epidermis via E-
cadherin. Although Langerhans cells are able to present anti-
gens to Tcells in local skin-draining lymph nodes, their role in
disease pathogenesis and the nature of the putative psoriasis
antigen remains unclear. Previous studies have shown that
Langerhans cell migration in non-lesional skin is impaired in
early-onset (before age 40; type I) psoriasis [30, 31] and re-
stored with anti-psoriatic biologic treatments [32]. This sug-
gests that loss of cell mobility may cause a dysregulated cuta-
neous immune response.
Keratinocytes
Keratinocytes are believed to be crucial in both the early
stages of disease pathogenesis and later amplification of
chronic inflammatory circuits. As the major constituent of
the epidermis, keratinocytes have structural and immunologi-
cal functions. They form the body’s first line of defence
against exogenous physical, chemical and microbial insults.
Genetic studies indicate a role for skin barrier dysfunction in
psoriasis since deletion of LCE3B and LCE3C genes,
encoding stratum corneum proteins involved in terminal dif-
ferentiation of the epidermis, was found to be associated with
psoriasis [33]. It is hypothesised that incomplete repair after
minor skin injury, due to LCE gene deletion, contributes to the
development of chronic inflammation [34].
Injury to the skin, resulting in cell death, causes the release
of antimicrobial peptides (AMPs) by keratinocytes. AMPs,
such as LL37, S100 proteins and β-defensins, are key medi-
ators of the innate immune response and have been implicated
in psoriasis pathogenesis. Specifically, genetic studies have
demonstrated an association between increased β-defensin
genomic copy number and risk of disease [35, 36]. AMPs
have been shown to be upregulated in psoriasis and its expres-
sion is reduced after successful treatment with systemic agents
[37]. These molecules have direct antimicrobial activity and
also help to modulate immune cells by promoting the upreg-
ulation of pro-inflammatory cytokines such as IL-6 and IL-10
and chemokines such as IL-8 (CXCL8) and CXCL10. This
mediates the recruitment of macrophages and neutrophils.
In addition to being a rich source of AMPs, keratinocytes
also release IL-1 family cytokines including IL-1β and IL-18,
which help to initiate the cutaneous inflammatory response to
injury. Keratinocytes contain inflammasomes, which are
multi-protein complexes that consist of caspase-1, the adaptor
protein ASC and a sensor protein (either a nod-like receptor
e.g. NLRP3 or a pyrin and HIN domain protein e.g. AIM2),
that detect sterile stressors and pathogens [38]. Activated
caspase-1 cleaves pro-IL-1 and pro-IL-18 into the mature,
active forms of the cytokines. IL-1β thus released has several
paracrine effects including the production of TNFα by local
keratinocytes and upregulation of leucocyte chemotactic pro-
teins e.g. selectins, which promote the skin infiltration and
activation of T cells. IL-18 and IL-1β are further involved in
the differentiation of Th1 cells and Th17 cells, respectively
(Fig. 2) [39, 40]. This sets up positive feedback loops as acti-
vated Th1 and Th17 cells release IL-22 and IL-17 (Th17 on-
ly), which drives keratinocyte proliferation and activation,
hence contributing to the formation of a cutaneous plaque. T
cells also upregulate S100 proteins in keratinocytes, which in
turn mediates further leucocyte chemotaxis.
Several genes expressed within keratinocytes that promote
innate responses to viral nucleic acids and are upregulated in
psoriatic skin lesions have been found by GWAS to confer
disease susceptibility. The RIG-I and MDA5 innate antiviral
receptors, encoded by the psoriasis-associated genes DDX58
and IFIH1, respectively, bind to viral double-stranded RNA
and promote the release of pro-inflammatory cytokines that
have been implicated in psoriatic lesion initiation such as type
I IFN, IL-1, IL-6, and IL-29 [19, 21, 41]. IL-29 signals
through a receptor encoded by IL28RA, which has also been
identified by GWAS [19]. The signalling cascade triggered by
RIG-I and MDA5 is regulated by the protein product of the
disease susceptibility gene RNF114 [42, 43]. Hence, dysregu-
lated antiviral immunity may contribute to the development of
psoriasis by promoting the over-production of pro-
inflammatory cytokines by keratinocytes.
Keratinocytes also produce VEGF during inflammatory
states, which induces angiogenesis by promoting the migra-
tion, survival and proliferation of endothelial cells, resulting in
the formation of an erythematous, vascular plaque. In support,
VEGF overexpression in mouse skin results in a psoriasiform
phenotype [44].
Neutrophils
Neutrophils are important in the early stages of psoriasis
as they are involved in the recruitment and activation of
T cells and the proliferation and differentiation of
keratinocytes [45]. Neutrophils are predominantly found
in the epidermis in psoriasis and are recruited by the
chemokines CXCL1, CXCL2, IL-8 and IL-18.
Activated neutrophils release pro-inflammatory cytokines
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such as IL-17, AMPs and proteases. AMPs are released
as neutrophil extracellular traps (NETs), which are web-
like structures that are composed predominantly of neu-
trophil DNA. NETs have been shown to mediate auto-
immune disease-associated organ damage [46] and have
been identified in psoriatic lesions [47]. Elastase is a
protease that is released by neutrophils in response to
TNFα or IL-8. It has several downstream effects, in-
cluding the induction of keratinocyte proliferation and
cleavage of cytokines into their active forms [48]. The
importance of neutrophil-keratinocyte crosstalk in early
psoriasis pathogenesis was highlighted by a recent re-
por t [49] , in which the ant i - IL-17A ant ibody
secukinumab caused a rapid reduction in cutaneous neu-
trophils alongside histological improvement in
keratinocyte abnormalities and downregulation of
keratinocyte-derived neutrophil chemoattractants e.g.
CXCL1.
Macrophages
The role of macrophages in psoriasis is not yet fully
characterised; however, they are speculated to contribute to
the disease as there is a threefold increase in cell numbers in
lesional skin, with evidence of normalisation after successful
treatment [24]. Mouse models with skin phenotypes that re-
semble human psoriasis support involvement from skin mac-
rophages in disease development and maintenance [50, 51].
Cutaneous macrophages can be identified by their expression
of CD163, and activated macrophages produce high levels of
TNFα and are likely to regulate angiogenesis via the release of
VEGF [52].
T cells
The importance of abnormal T cell activation in the pathogen-
esis of psoriasis has been highlighted by several genetic stud-
ies that demonstrate a strong disease association with the
HLA-Cw6 allele, as described above. GWAS have also iden-
tified multiple genes involved in the IL-23/T17 axis e.g.
IL23R, IL23A and IL12B (Fig. 3) [18, 53], which emphasises
this particular T cell subset as being crucial to the disease
process. Further, a missense mutation (R381Q) in IL23R
was shown to impair IL-23-induced Th17 activation and ef-
fector function and confer protection against psoriasis [54].
Hence, aberrant IL-23 signalling and Th17 activity contribute
to chronic inflammation in psoriasis.
A key role for Tcells is also indicated by their prevalence in
lesional skin biopsies [55]. This is supported by the effective-
ness of several T cell-directed therapies in causing disease
resolution. The first successful drug was DAB389IL-2, an IL-
2 fusion protein that causes apoptosis of activated T cells i.e.
cells expressing functional IL-2 receptors [56]. The observed
beneficial effects of other agents such as abatacept (CTLA-4-
Ig), which blocks Tcell co-stimulation, and alefacept, an LFA-
3-Ig fusion protein that inhibits effector memory T cell activa-
tion, further re-enforced the important pathogenic activity of
this cell type in psoriasis [57–59]. Clinical improvements with
these agents were associated with a decrease in the number of
T cells and DCs infiltrating skin lesions. Xenotransplantation
mouse models provided additional evidence, since asymptom-
atic skin grafts developed typical features of psoriasis after
injection of activated immunocytes [60]. IL-23-specific
monoclonal antibodies prevented such lesions from develop-
ing, highlighting the pathogenic importance of Th17 cells
[61].
Multiple T cell subsets, each producing a distinct range of
cytokines, have been characterised that are relevant to the
disease process, including CD4+ Th1, Th17 and Th22 that
produce IFNγ/TNFα, IL-17/IL-22 and IL-22, respectively
(Fig. 2) [62]. Naive CD4+ T cells differentiate into Th1 cells
in the presence of IL-12 [63]; lineage specification of Th17
cells is regulated by IL-6, IL-1β and TGF-β [64, 65] and
Th22 cells require TNFα and IL-6 [66, 67]. Subsequent ex-
posure to IL-23 and IL-21 promotes the activation and prolif-
eration of mature, inflammatory Th17 cells [65]. Since there
are CD8+ T cells that produce the same cytokines as CD4+
Th17 cells, the term ‘T17 cells’ has been used to encompass
all IL-17-producing cells, which also includes T cells express-
ing the non-variant γδ T cell receptor [68, 69]. Psoriatic skin
lesions have greatly increased numbers of γδ T cells com-
pared with healthy controls, and an IL-17-producing γδ Tcell
population has been identified in the dermis, which may be
highly relevant in disease pathogenesis [69, 70].
The role of cytokines in psoriasis
TNFα
TNFα is produced by several different cells types in the con-
text of cutaneous inflammation, including macrophages,
keratinocytes, Th1 cells, T17 cells, Th22 cells and BDCA-1
− inflammatory DCs [71, 72]. Although parts of the literature
are conflicting [73], there is evidence that circulating levels of
TNFα (in addition to IFNγ, IL-12) are elevated in psoriasis
and correlate with disease severity [74, 75].
TNFα regulates the ability of antigen presenting cells such
as DCs to activate T cells [76]. It induces the expression of C-
reactive protein (part of the acute phase response), several
cytokines such as IL-6 (which mediates T cell proliferation
and keratinocyte hyperproliferation), and chemokines includ-
ing CCL20 (recruits myeloid DCs and T17 cells) and IL-8 (for
recruitment of neutrophils). Through the upregulation of in-
tercellular adhesion molecule-I (ICAM-1), TNFα promotes
the infiltration of inflammatory cells such as T cells and
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monocytes into the skin. It also facilitates IL-23 production by
DCs and enhances the effects of other cytokines relevant to
psoriasis pathogenesis such as IL-17. Therefore, TNF antag-
onists mediate part of their effect via suppression of the IL-23/
T17 axis [24].
TNFα has a broad range of effects since TNF receptors
(TNFR) are expressed on multiple cell types. There are two
types of receptors, TNFR1 and TNFR2. Whereas TNFR2 is
expressed predominantly on endothelial and haematopoietic
cells, TNFR1 is present on nearly all cell types [77]. Once acti-
vated by engagement with TNFα, TNFR modulate multiple
aspects of cell function such as proliferation, survival, activa-
tion, differentiation and apoptosis, by activating signalling cas-
cades involving NF-κB, mitogen-activated protein kinase
(MAPK) and c-Jun N-terminal kinase [78, 79]. Although
TNFα blockade is very effective therapeutically, which sup-
ports its role in disease pathogenesis, the diverse actions of the
cytokine have resulted in numerous drug-associated side ef-
fects.Therefore,more targeted immunotherapies arenowbeing
investigated.
IFNγ
In addition to TNFα, Th1 cells are a key source of IFNγ, which
is a type II IFN. It is also secreted byDCs and natural killer (NK)
cells. Signal transducer and activator of transcription (STAT) 1 is
activated downstream of IFNγ and this regulates many genes
that are found to be expressed in psoriatic skin lesions [80].
RNA microarrays have demonstrated that a large number of
IFNγ-related genes are differentially regulated in psoriasis
[81]. However, it was shown that antagonism of IFNγ using a
humanised monoclonal antibody does not significantly improve
psoriasis [82]. Further, in a clinical trial of an IL-23-specific
monoclonal antibody, there was no effect on IFNG expression
in patients with psoriasis despite a complete clinical and histo-
logic response, in contrast to the significant reduction in IL17
messenger RNA levels observed [83]. This suggests that IFNγ
is not critical in sustaining chronic psoriasis lesions.
It is instead postulated that IFNγ is more relevant in the
early stages of disease, through the activation of antigen pre-
senting cells [84]. It promotes the release of IL-1 and IL-23
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Fig. 3 The IL-23/T17 pathogenic axis is an important therapeutic target
in psoriasis. IL-23 is a heterodimeric cytokine that is released by dendritic
cells and binds to the IL-23 receptor (IL23R) on T17 cells. IL-23R is
associated with Jak2 and Tyk2, which activate STAT3 molecules,
resulting in the upregulation of IL-17A. Engagement of IL-17R on
keratinocytes with IL-17A homodimers or IL-17A/IL-17F heterodimers
induces the activation of NF-κB dimers, which translocate to the nucleus
and drive the transcription of pro-inflammatory cytokines, chemokines
and antimicrobial peptides. Numerous genes (yellow) encoding proteins
involved in the IL-23/T17 pathway have been shown by genome-wide
association studies to confer psoriasis susceptibility. Following activation
of IL-17R, ACT1 (encoded by TRAF3IP2) interacts with TRAF proteins
and the IκB kinase complex (IKK). IKK subsequently phosphorylates the
inhibitory proteins IκB (IκBα is encoded by NFKBIA), which normally
form cytoplasmic complexes with NF-κB. Once phosphorylated, IκB is
subject to ubiquitin-induced proteasomal degradation, resulting in the
nuclear translocation of NF-κB. Further, the protein products of TNFAIP3
and TNIP1, A20 and ABIN1, respectively, physically interact to enable
the ubiquitin-mediated destruction of NEMO (a regulatory protein that
activates IKK). Several medications for psoriasis (red) target components
of the IL-23/T17 immune axis
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from DCs, which in turn drives T17 and Th22 cell differenti-
ation and activation. IFNγ also stimulates chemokines (e.g.
CXCL10, CXCL11) and adhesion molecule release from
keratinocytes, thus facilitating the recruitment of lymphocytes
to inflammatory plaques. Although it is known to have an
anti-proliferative effect on keratinocytes, this effect is abrogat-
ed in psoriatic lesions via the upregulation of suppressor of
cytokine signalling (SOCS) 1 in response to high levels of
IFNγ [85].
Type I IFN
Type I IFNs comprise IFNα and IFNβ, amongst others [86].
Several observations have indicated an important role for
these cytokines in psoriasis development, particularly in the
early stages. Treatment with type I IFN for conditions such as
hepatitis and multiple sclerosis has been shown to exacerbate
existing psoriasis vulgaris and induce new lesions [87, 88].
The type I IFN signalling pathway is activated in lesional
keratinocytes and patients have abnormal serum levels of
IFNs [89, 90]. In further support, an increase in IFNα level
in xenograft mouse models precedes the development of pso-
riatic changes and anti-IFNα antibodies block classical psori-
atic skin changes such as T cell infiltration into plaques [28].
As discussed above, plasmacytoid DCs, which infiltrate
psoriatic skin lesions, are a major source of type I IFN [28]
and this promotes myeloid DC phenotypic maturation and
activation, thus facilitating T cell priming. Type I IFN signal-
ling modulates the production of IFNγ and IL-17 [91, 92] and
has been implicated in the differentiation and activation of T
cells, in particular Th1 and T17 cells [93]. Thus, it may drive
downstream inflammatory circuits, leading to keratinocyte
hyperproliferation. In addition to the indirect modulation of
T cell responses via regulation of DCs, type I IFN may have
direct pro-survival and pro-proliferative effects on Tcells [94].
Finally, type I IFNs are rapidly induced in many different cell
types in response to viral infections. Since genetic studies
have indicated the importance of innate antiviral immune re-
sponses in psoriasis pathogenesis, this also underlines type I
IFN as a critical disease cytokine. Specifically, several genes
regulating type I IFN production (e.g. DDX58, IFIH1,
RNF114) and signalling (e.g. TYK2) have been associated
with disease susceptibility in GWAS.
IL-23
IL-23 is a heterodimer that is composed of an IL-23p19 sub-
unit (encoded by IL23A) and IL-12/IL-23p40 (shared with IL-
12 and encoded by IL12B) (Fig. 3). It binds to IL-23R, which
is associated with Jak2 and Tyk2. Engagement of the receptor
triggers a signalling cascade that involves activation of
STAT3. IL-23 is released by DCs and macrophages and me-
diates the terminal differentiation and activation of T17 cells
(including induction of IL-17A and IFNγ), activation of
keratinocytes and upregulation of TNFα expression in mac-
rophages. Genetic studies that link single nucleotide polymor-
phisms in/near IL-23R, IL23A, IL12B, TYK2 and STAT3 with
psoriasis susceptibility have highlighted IL-23 as a critical
cytokine in disease pathogenesis [18–21]. In support, psoriasis
lesions have elevated levels of IL-23 expression [95] and this
is reversed after successful treatment with medications such as
etanercept [96] and alefacept [97]. Further, anti-IL-12/IL-23
and anti-IL-23 agents are highly effective therapeutic agents
[98]. Evidence from mouse models, in which psoriasiform
histological changes arise from intradermal injection of IL-
23 or overexpression of IL-12/IL-23p40 in keratinocytes, also
indicate the importance of this cytokine [99].
IL-17A
IL-17A belongs to the family of pro-inflammatory cytokines
that comprises IL-17A-F [100]. It is overexpressed in psoriasis
(both skin and blood [74, 101]) and its involvement in the
immunopathogenesis of psoriasis has been increasingly
recognised [102]. Given that IL-17 may promote the develop-
ment of cardiovascular diseases [103], and the established link
between psoriasis and such co-morbid conditions, targeting of
IL-17 therapeutically may have benefits beyond the sole at-
tenuation of skin inflammation. However, the biological ef-
fects of IL-17A in various tissues are complex. Indeed, it may
also help to stabilise atherosclerotic plaques [104], which em-
phasises the need to enrol patients receiving IL-17 inhibitors
in long-term safety registries.
Lesional psoriatic T cells produce large amounts of IL-17A
when activated ex vivo; however, T cells from healthy skin do
not produce IL-17Awith the same stimuli [105]. Analysis of
the psoriasis transcriptome also reveals enrichment for IL-17A
genes [106]. More recently, IL-17A blocking agents have
been shown to have rapid and high efficacy in clinical trials,
as described later, further emphasising the pathogenic role of
IL-17A signalling in psoriasis [107–109].
IL-17A is produced by T17 cells, neutrophils, mast cells
and NK cells. Keratinocytes are the predominant cells that
express IL-17 receptors (IL-17R; likely consisting of two IL-
17RA subunits complexed with one IL-17RC subunit) in pso-
riasis [110]. The active form of IL-17A consists of either IL-
17A homodimers or IL-17A-IL-17F heterodimers; the former
having greater biological activity. Engagement of IL-17R in-
duces the activation of NF-κB signalling. GWAS have impli-
cated several genes encoding components of the NF-κB path-
way in psoriasis susceptibility including TNFAIP3, TNIP1,
NFKBIA, REL and TRAP3IP2 (Fig. 3) [18–21]. For example,
a loss of function coding variant in TRAP3IP2 is associated
with psoriasis [20]. TRAP3IP2 encodes ACT1, which is in-
volved in IL-17 signalling, and Act-1-deficient mice demon-
strate upregulated T17 cell responses and spontaneous skin
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inflammation [111]. This underscores the immunological in-
sights that can be gained from genetic data.
The downstream expression of a large number of genes in
response to IL-17A has been shown in a three-dimensional
human epidermis model (419 gene probes upregulated and
216 gene probes downregulated) [112]. Keratinocytes are
stimulated by IL-17A to produce AMPs; pro-inflammatory
cytokines such as IL-19 (driving epidermal hyperplasia), IL-
1, IL-6, and IL-23; and chemokines such as IL-8. In addition
to promoting the mobilisation and activation of neutrophils,
IL-8 is also a chemotaxin for T cells and NK cells. Although
the role of regulatory T cells in the pathogenesis of psoriasis
remains to be fully elucidated, IL-6 is thought to render effec-
tor Tcells refractory to regulatory Tcell-mediated suppression
[113]. IL-17A also increases production of the chemokine
CCL20 [114, 115] and ICAM-1, which facilitate cutaneous
recruitment of DCs and T cells.
Taken together, IL-17A is crucial to establishing positive
feedback loops such that epidermal hyperplasia and the cuta-
neous inflammatory response are sustained and amplified. For
example, recruited DCs may secrete more IL-23, which pro-
motes further T17 cell activation and hence release of IL-17A.
This influences keratinocytes, leading to the recruitment of
more DCs and T cells to the inflamed skin. IL-17 has recently
been shown to act in synergy with TNFα to induce pro-
inflammatory cytokine production by keratinocytes [115].
Indeed, genes that are synergistically regulated by IL-17 and
TNFα were more effectively blocked by anti-IL-17A than
TNF antagonists [102], suggesting that IL-17A may have a
dominant pathogenic effect.
IL-22
IL-22 is a member of the IL-10 family of cytokines and has
been found to be upregulated in the skin and sera of patients
with psoriasis [116, 117]. Expression is also reduced follow-
ing anti-psoriatic therapies [117]. The production of IL-22 by
Th22 cells and Th17 cells is induced by IL-23 and it mediates
mu l t i p l e e f f e c t s o n k e r a t i n o c y t e s , i n c l u d i n g
hyperproliferation, differentiation, migration, and pro-
inflammatory cytokine and AMP production [118, 119]. IL-
22 has been shown to act in synergy with IL-17A to induce
AMP production by keratinocytes [120]. Blockade of IL-22
in vivo or genetic deletion caused reduced IL-23-induced epi-
dermal hyperplasia [121], and IL-23-mediated epidermal hy-
perplasia in a murinemodel of psoriasiform skin inflammation
was found to be dependent on IL-22 [121]. These data high-
light potential crosstalk between the IL-23/T17 pathway and
IL-22/Th22. However, in contrast to the IL-23/T17 pathway,
there is a lack of genetic data in support of a role for IL-22 in
disease pathogenesis. Further, trials of a human monoclonal
antibody targeted against IL-22 (fezakinumab) were
discontinued since preliminary analyses showed that the
efficacy endpoints could not be achieved [122]. The negative
findings from both genetics and clinical studies suggest that
IL-22 may not be as critical to the disease process as had
initially been anticipated from earlier immunological studies.
Pustular psoriasis
Pustular psoriasis is a rare, severe subtype of psoriasis that has
been shown by genetic studies to have a distinct aetiology
from psoriasis vulgaris. In particular, a lack of association of
pustular psoriasis with the PSORS1 locus has been demon-
strated, in striking contrast to psoriasis vulgaris [123]. It is
characterised clinically by the presence of sterile pustules on
variably erythematous skin and histologically by diffuse der-
mal neutrophilic infiltration and micropustules in the epider-
mis [124, 125]. It encompasses generalised pustular psoriasis,
in which patients experience acute flares of widespread cuta-
neous pustulation associated with systemic upset, and chronic,
localised forms such as palmoplantar psoriasis and
acrodermatitis continua of Hallopeau.
Recently, IL-1 family cytokines have been shown to
have a potential pathogenic role in pustular psoriasis
since loss of function, autosomal recessive mutations
in IL36RN were described in association with this dis-
ease subtype [126–128]. Targeted sequencing studies
further revealed that mutations in IL36RN are not asso-
ciated with psoriasis vulgaris, emphasising distinct path-
ogenic mechanisms for pustular and plaque forms of
psoriasis and the potential for stratification of psoriasis
subtypes using genetic biomarkers [129]. IL36RN en-
codes an antagonist (IL-36Ra) that blocks innate im-
mune IL-1 family cytokines (IL-36α, IL-36β and IL-
36γ) from binding to their receptor (IL-1RL2) [130].
This prevents subsequent activation of the NF-κB path-
way. Therefore, IL-36Ra deficiency leads to unopposed
IL-1 activity that may result in the significant cutaneous
neutrophil recruitment that is observed in pustular pso-
riasis. IL-36 cytokines also cause upregulation of IL-23
by DCs and keratinocytes [131], IL-6 and IL-8, which
helps to sustain cutaneous inflammation.
In further support of a role for aberrant IL-1 signalling in
pustular psoriasis, the disease is associated with pathogenic
mutations in AP1S3, silencing of which has been shown to
disrupt the endosomal translocation of Toll-like receptor 3
(TLR3), leading to impaired IFNβ induction [132]. Given that
IFNβ downregulates the production of IL-1 [133], it is possi-
ble that mutations in AP1S3, which encodes a subunit of adap-
tor protein complex 1 and is involved in clathrin-mediated
vesicular transport of proteins between the trans-Golgi net-
work and endosomes, result in IL-1 over-production. By vir-
tue of the aforementioned pathogenic insights delivered by
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genetic studies, IL-1 blockade is now emerging as a promising
therapeutic strategy for this clinical variant.
Pustular psoriasis is also associated with missense muta-
tions in CARD14 [134–136]. CARD14 is highly expressed in
the skin and encodes a protein involved in TRAF2-dependent
NF-κB activation [137]. It has been previously implicated in
psoriasis vulgaris [138], which suggests some potential shared
disease pathways in distinct subtypes of psoriasis.
Update on therapeutics
As the pathogenic mechanisms have become better defined,
there has been a shift towards the design of more targeted
treatments in psoriasis (Table 1). Specific cytokines pertinent
to the development of disease have been selected as drug
targets in the hope of effective suppression of pathogenic im-
mune responses whilst reducing the risk of global suppression
of protective immunity, thus potentially improving the safety
profiles of the medications.
TNF antagonists
TNF antagonists have proven to be highly effective for the
treatment of psoriasis. The three agents currently approved
for use in moderate/severe psoriasis are infliximab, a chimeric
neutralising monoclonal antibody, adalimumab, a fully
humanised IgG1 monoclonal antibody, and etanercept, a re-
combinant fusion protein comprising an Fc domain of human
IgG1 monoclonal antibody and the ligand binding domain of
the TNFα receptor. Effective treatment causes decreased
numbers of T cells and DCs and reduced levels of their secret-
ed cytokines [24, 139]. In particular, successful therapy was
found to be associated with downregulation of genes involved
in the differentiation and function of Th17 cells, suggesting
that TNF antagonists exert their effect via the modulation of
the IL-23/T17 axis. This may be attributable to TNFα promot-
ing IL-23 synthesis in DCs. Etanercept treatment was also
shown to reduce lesional DC expression of co-stimulatory
molecules in vitro, thus impairing DC-T cell interactions and
the activation of allogeneic T cells [24].
However, blockade of TNFα may lead to serious ad-
verse events, including reactivation of latent tuberculosis,
and this has prompted more rigorous screening investiga-
tions prior to commencing all biologic agents [140]. Some
studies have also described an association between treat-
ment and an increased incidence of malignancy such as
lymphoma [141, 142]. There are reports of TNF antago-
nists rarely promoting the development of demyelinating
disease, and a potential underlying mechanism has been
unravelled through the discovery of a multiple sclerosis-
associated genetic variant that translates into the produc-
tion of an endogenous TNF antagonist called Δ6-TNFR1
[143, 144]. This soluble protein comprises the extracellular
domain of TNFR1, but lacks the transmembrane or cyto-
plasmic domains. It can bind and neutralise TNF with
high affinity, thus preventing potentially neuroprotective
cellular signalling through membrane-bound TNFR1.
Finally, TNF antagonists have been associated with a de
novo, paradoxical onset of pustular psoriasis mostly locat-
ed on the palms and/or soles, for which a mechanism is
currently unknown [145].
Table 1 Targeted therapies for psoriasis
Therapeutic agent Target Agent type Stage of development
Infliximab TNFα Chimeric monoclonal antibody Approved
Adalimumab TNFα Human monoclonal antibody Approved
Etanercept TNFα Soluble TNFα receptor-IgG fusion protein Approved
Ustekinumab IL-12/IL-23p40 Human monoclonal antibody Approved
Tildrakizumab, guselkumab IL-23p19 Human monoclonal antibody Phase III studies ongoing
Ixekizumab IL-17A Humanised monoclonal antibody phase III Studies ongoing
Secukinumab IL-17A Human monoclonal antibody Approved
Brodalumab IL-17RA Human monoclonal antibody Development halted
Apremilast PDE-4 Small molecule inhibitor Approved
Tofacitinib JAK1/JAK3 Small molecule inhibitor Phase III studies completed; under FDA review
Ruxolitinib JAK1/JAK2 Small molecule inhibitor Phase II studies completed
CF101 A3 adenosine receptor Small molecule agonist Phase II/III studies completed
Anakinra IL-1R Soluble recombinant IL-1Ra Phase II study ongoing
MABp1 IL-1α Humanised monoclonal antibody Phase II study completed
Canakinumab IL-1β Human monoclonal antibody Not currently in trial
Gevokizumab IL-1β Humanised monoclonal antibody Not currently in trial
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IL-12/IL-23 inhibitors
Since the characterisation of a dominant pathogenic role for
the IL-23/T17 axis in psoriasis by GWAS, several drugs
targeted against components of this pathway have been stud-
ied with reported successful outcomes (Fig. 3). Ustekinumab
is a Food and Drug Administration (FDA)-approved
humanised monoclonal antibody that neutralises the p40 sub-
unit common to IL-23 and IL-12. The antibody prevents the
binding of IL-23 and IL-12 to their receptors, thus inhibiting
T17 and Th1 signalling pathways. It has been shown to be a
highly efficacious treatment, with greater than 60 % of treated
patients achieving at least 75 % reduction in their baseline
Psoriasis and Severity Index (PASI-75) at 12 weeks compared
with 3 % of the control group [146, 147]. There is also a
reported superior clinical effect compared with etanercept
[148], suggesting that IL-23 may have a more prominent role
than TNFα in psoriasis pathogenesis. Indeed, IL-23 levels
remain high in patients who fail TNF antagonists, which en-
able ongoing T17 activation [139]. Although limited follow-
up data is available, the safety profile of ustekinumab to date
appears to be more favourable than TNF antagonists, which
may be due to the intact TNFα-mediated innate immune re-
sponses that result from IL-23 antagonism.
There are emerging reports of successful treatment of dif-
ferent subtypes of pustular psoriasis with ustekinumab
[149–152]. However, the case reported of successful treatment
of acrodermatitis of Hallopeau, a severe and often refractory
form of pustular psoriasis affecting distal fingers and toes,
required co-therapy with acitretin and higher than standard
doses of ustekinumab in order to achieve complete clinical
resolution [151]. Further assessment of this medication within
adequately powered clinical trials is thus warranted; however,
this is challenging given the lower prevalence of this form of
psoriasis.
There are encouraging results from clinical studies of
monoclonal antibodies that target the unique p19 subunit of
IL-23 in psoriasis vulgaris [153]. Seventy-four percent of pa-
tients treated with tildrakizumab, a monoclonal anti-p19 IgG1,
achieved PASI-75 after 16 weeks compared with 4.4 % of
individuals in the placebo group in a phase II trial. In a study
of guselkumab (anti-p19), 81 % of patients achieved PASI-75
after 16 weeks in the treatment group, compared with 71 % of
those receiving adalimumab and 4.8 % of those receiving
placebo.
IL-17 inhibitors
IL-17A is a central driver in disease pathogenesis; hence, IL-
17 inhibitors have been extensively researched for the treat-
ment of psoriasis. Secukinumab and ixekizumab are
neutralising humanised monoclonal antibodies (IgG4 and
IgG1, respectively) that bind to IL-17A and brodalumab binds
to the IL-17 receptor A subunit.
Secukinumab received FDA approval for the treatment of
moderate/severe psoriasis in January 2015. It demonstrated
clinical efficacy in phase II trials, with 82% of treated patients
achieving PASI-75 compared with 9 % of those receiving
placebo [154]. This agent was shown to bemore effective than
etanercept in the 52-week randomised, double-blind, placebo-
controlled, parallel-group, phase III FIXTURE study, with
similar incidences of adverse events [155]. The trial also
showed more rapid effects with secukinumab as clinical re-
sponse (defined as a 50 % reduction in mean PASI) was
achieved sooner with secukinumab (median 3 weeks with
300 mg and 3.9 weeks with 150 mg) than etanercept (median
7 weeks). Candidal infections were more common in those
treated with secukinumab than etanercept, which is likely at-
tributable to the important role for IL-17A in mucocutaneous
immunity against fungi. All candidal infections were, howev-
er, either self-limited or resolved with standard treatments and
none required cessation of secukinumab. A second
randomised phase III trial (ERASURE), comparing
secukinumab with placebo, demonstrated superior responses
in the treatment group at 12 weeks [155].
Phase II trial data of ixekizumab showed that 82 % of
treated patients achieved PASI-75 at 12 weeks with no asso-
ciated serious adverse events [109]. A rapid clinical response
was observed, with many achieving near maximal improve-
ment within the first 6 weeks of treatment, which is faster than
that observed with other available therapies, including TNF
antagonists. Phase III studies of ixekizumab are ongoing
(https://clinicaltrials.gov).
Mechanistic studies have demonstrated decreased expres-
sion of a broad range of immune-related genes in response to
secukinumab treatment, including T17-related transcripts
(IL22, IL17F and IL8), Th1-related genes (IFNG and IL12B)
and other innate immune inflammatory genes (TNF, IL6 and
IL1B), which may account for the potency of the medication
[156]. There also was evidence of decreased epidermal hyper-
plasia, indicating keratinocyte modulation, and reduced infil-
tration of CD3+ and IL-17+ cells in lesions. A later study
showed a reduction in the inflammatory cell infiltrate
(CD3+, CD11c+ and CD-LAMP+ cells) in response to
ixekizumab, indicating effects on both T cells and DCs
[102]. The medication modulated gene expression rapidly,
with normalisation (i.e. reduction by at least 75 %) of 60 %
of transcriptome genes relevant to psoriasis after only 2weeks,
compared with 10 % of disease-related genes normalised by
etanercept. This study also highlighted the wide-ranging ef-
fects of IL-17, since hundreds of psoriasis-associated genes
were normalised by ixekizumab.
Brodalumab has a potentially wider range of action as it
antagonises the receptor that binds IL-17A, IL-17F and IL-
17A/F heterodimers. A phase II clinical trial showed that 82%
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of treated patients reached PASI-75 at week 12 [107], and
phase III studies demonstrated superior efficacy of
brodalumab compared with both placebo and ustekinumab
for all primary endpoints [157]. Despite these promising re-
ports, there has been recent concern over potential links be-
tween brodalumab and suicidal ideation since two patients
enrolled in the published clinical studies committed suicide.
Although no causality has been established between these
events and brodalumab, it underlines our current relatively
limited understanding of the safety profiles of these
medications.
Phosphodiesterase inhibitors
The oral phosphodiesterase-4 (PDE-4) inhibitor apremilast
prevents the conversion of 3 ′-5 ′-cyclic adenosine
monophosphate (cAMP) to AMP. Its beneficial effect is thus
attributable to increased levels of cAMP, which reduces in-
flammation by downregulating cytokines such as TNFα and
IL-23. It also upregulates the production of anti-inflammatory
molecules such as IL-10 [158]. Phase II and III study data
demonstrated superior benefit in the treatment groups com-
pared to placebo, with a favourable safety profile reported,
and it was approved by the FDA and European Medicines
Agency (EMA) for the treatment of moderate/severe psoriasis
in 2014 [159].
Janus kinase inhibitors
Janus kinases (JAK) are cytoplasmic protein tyrosine kinases
that mediate the activation of STAT proteins. JAK/STAT in-
tracellular signalling regulates the expression of pro-
inflammatory genes. Numerous cytokines that are upregulated
in psoriatic skin lesions and involved in T cell proliferation,
activation and survival, such as type I and III IFNs and IL-23,
use the JAK/STAT pathway; however, there some exceptions,
including TNFα and IL-17. There are four members of the
JAK family, JAK1, JAK2, JAK3 and TYK2. JAKs act in pairs
and the novel inhibitors that are currently being evaluated in
clinical trials have varying efficacy for each of the JAKs.
TYK2 is involved in modulation of T17 cell responses, and
although there are no selective TYK2 inhibitors currently in
clinical trials, the pathogenic missense mutations in TYK2
discovered by GWAS emphasise its role in disease pathogen-
esis and the utility of pursuing it as a novel drug target [19].
Tofacitinib is a small molecule that preferentially inhibits
JAK1 and JAK3. Phase II study data demonstrated a PASI-75
response in 67 % of patients with moderate/severe plaque
psoriasis receiving 15 mg daily [160]. In this study, the side
effects included dose-dependent increases in lipids (which
returned to baseline after cessation of treatment) and mild
decreases in haemoglobin and neutrophil counts. Although
small molecules generally have less efficacy when compared
with biologic agents, their associated advantages include oral
administration (or topical, as below) and reduced cost.
Small molecules less than 500 Da in molecular weight are
able to cross the stratum corneum, so may be used as topical
treatments [161]. Topical 2 % tofacitinib formulations were
well tolerated and showed promising efficacy in a recent
vehicle-controlled trial [162]. Ruxolitinib predominantly in-
hibits JAK1 and JAK2 and topical formulations have previ-
ously been tested [163]. This demonstrated a 53 % and 54 %
decrease in mean ‘total lesion score’ (assessing scaling, red-
ness and thickness) after treatment with 1 % and 1.5 %
ruxolitinib ointments, respectively, compared with 32 % for
vehicle. No significant adverse effects were reported.
A3 adenosine receptor agonists
A3 adenosine receptors (A3AR) are G protein coupled recep-
tors that bind to adenosine. They were found to be highly
expressed in peripheral blood mononuclear cells from psoria-
sis patients [164]. Activation of A3AR by the agonist CF101
has been shown to reduce NF-κB signalling and promote ap-
optosis of inflammatory cells. Pro-inflammatory cytokines
such as TNFα, IL-6 and IL-12 are also downregulated.
CF101 has subsequently been tested in a phase II clinical trial
[165]. Orally administered CF101 (2 mg twice daily) resulted
in a PASI-50 response in 35.3 % of patients, with only mild
side effects reported.
IL-1 antagonists
Given the potential importance of dysregulated IL-1 signal-
ling in the pathogenesis of pustular psoriasis, IL-1 blockers
have been investigated for use in the treatment of this clinical
phenotype, with successful cases described [166–168]. The
agent anakinra has been used, which is a recombinant form
of the IL-1 receptor antagonist (IL-1Ra) that prevents both IL-
1α and IL-1β signalling. However, randomised control trial
data is lacking and the reported cases of incomplete clinical
response suggest that IL-1 signalling may not play a dominant
pathogenic role in all patients with pustular psoriasis [151,
169–171].
Conclusion
A limitation of the current clinical studies is the lack of long-
term data, which is particularly relevant when considering the
safety profile of the medications. For example, efalizumab
was first approved in 2003 for the treatment of moderate/
severe psoriasis but later withdrawn from the market in 2009
due to safety concerns. It is a humanised, monoclonal anti-
body that blocks the interaction between CD11a/LFA-1 on T
cells and ICAM-1 on antigen presenting cells. Efalizumabwas
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withdrawn after progressive multifocal leukoencephalopathy,
a potentially fatal central nervous system infection associated
with immunosuppression, was reported in four patients receiv-
ing treatment [172]. Further, although biosimilar alternatives
to biological agents that have lost their patent protection are of
considerable financial interest, the importance of critical as-
sessments of their safety, quality and efficacy relative to the
biological reference product prior to use in patients must be
emphasised [173].
Careful monitoring of all new and existing therapies and
recording of data inmulti-centre, large-scale registries are vital
to ensuring adverse events are promptly recognised. It will
also be important for clinical studies to stratify patients ac-
cording to detailed phenotype and genotype information.
This will help to identify biomarkers of drug response and
represent a shift towards the practice of personalised medi-
cine, in which an individual is prescribed a specific treatment
that is predicted to have therapeutic success and a favourable
safety profile, on the basis of their genetic profile.
Although further research is warranted, current clinical trial
data on new treatments are helping to improve our understand-
ing of the immunopathogenesis of psoriasis. Indeed, psoriasis
research is a leading example of the translational potential of
data from basic science studies such as GWAS, which have
delivered mechanistic insights into disease pathways. These
have subsequently informed the design of powerful new treat-
ments that are able to act faster, more effectively and in a more
targeted manner. Improved specificity of drug targets reduces
the chance of ameliorating the body’s protective immunity
against microbes, which is currently a limitation of agents
such as TNF antagonists. Although late-stage clinical trials
for several medications are still underway, there appears to
be increasing hope for the millions of individuals worldwide
suffering from this debilitating and disfiguring disease.
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